Comparative Toxicity Profiles of Two Platinum Doublets: Real Life Experience from a Cancer Unit Jessop S, Jeffs Y P, Thomas E, Azher M, Adu Poku K, Sa'D A, Prasad B, Egan A, Bulusu V R Primrose Oncology Unit, Bedford Hospital Bedford UK Introduction Platinum doublets remain the standard of care for palliative chemotherapy in lung cancer. We report on the toxicities experienced by the EGFR wild type patients treated with two different carboplatin doublets in a cancer unit. This was a follow up study to our earlier work on carboplatin/ pemetrexed doublet which highlighted the survival and toxicities1. Methods Case records and chemotherapy charts were reviewed from January 2013 to September 2014. Demographics, tumour stage, WHO performance status (PS) and toxicities (Common Toxicity Criteria version 4) were recorded. Comparative toxicity profiles were analysed for carboplatin/pemetrexed (CP) and carboplatin/oral vinorelbine (CV) doublets. Results Patient characteristics Pemetrexed carboplatin Oral vinorelbine carboplatin Total Number Male Female Median age (range) Median PS (range) 14 4 10 69y (50-81) 1 (1-2) 12 9 3 71.5y (47-84) 1 (0-2) 26 13 Pemetrexed carboplatin Oral vinorelbine carboplatin Median cycles Toxicity > grade 2 Dose delays Common toxicities 3 Fatigue Neutropenia Anaemia Pancytopenia 28% 0% 8% 50% Conclusions ≥ Grade 2 toxicities were rare with CV. The most common ≥ Grade 2 toxicities with CP were fatigue, neutropenia, anaemia. 28% of patients on CP required dose reductions or cycle delays. In our experience, carboplatin and oral vinorelbine is a well-tolerated regimen with no dose reductions or cycle delays and an acceptable toxicity profile. Reference: 1. Pemetrexed and carboplatin (PC) doublet in advanced non squamous non-small cell lung cancer. Real life experience from a Cancer Unit. Jessop S, Jeffs Y P, Adu-Poku K, Thomas E, Azher M, Hicks P, Egan A, Bulusu V R Lung Cancer Vol 83, Suppl 1, 2014 susan.jessop@bedfordhospital.nhs.uk